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Autonomic nervous system (ANS) in heart 
failure (HF)
In chronic HF, it has been recognized that complex ANS 
imbalances including loss of parasympathetic nervous 
system (PNS) inhibition of sympathetic nervous system 
(SNS) reflex arcs exist and ANS balance can be deteriorated 
during heart failure exacerbation (1-3). Whereas SNS 
activation maintains cardiac output acutely by positive 
inotropic and chronotropic effects, however, chronic 
autonomic dysregulation with increased SNS activity and 
reduced PNS lead to progressive myocardial dysfunction, 
neurohormonal activation and increased risk of malignant 
arrhythmias and sudden cardiac death in patients with 
HF (4,5). Over-activation of SNS and attenuation of PNS 
input have long been known to be a cardinal feature in the 
pathophysiology of cardiac remodeling and systolic HF. In 
the study by Cohn et al., in fact, the authors reported that 
plasma norepinephrine levels were independently predictive 
of mortality in patients with systolic HF (6).
ANS in pulmonary hypertension
In recent years, clinical relevance of ANS disturbances 
in pulmonary arterial hypertension (PAH) has attracted 
attention as a new therapeutic target irrespective of 
the existence of HF (7,8). PAH is a chronic pulmonary 
vascular disease characterized by increased pulmonary 
vascular resistance (PVR) leading to right ventricular (RV) 
failure with associated ANS disturbances (9). In the study 
by Chen et al., pulmonary artery denervation (PADN) 
using catheter ablation improved hemodynamic function, 
exercise capacity and reduced PAH-related events and 
death in patients with PAH (mean PA pressure ≥25 mmHg 
at rest) of different causes (7). Given the fact that right 
HF in PAH is the consequence of increased arterial 
afterload, a full description of the cardiopulmonary unit 
is required (10). The cardiopulmonary unit is composed 
of two functional subsystems: the RV (contractility 
and chamber stiffness) and the pulmonary circulation 
(resistance and compliance). An adapted RV in PAH 
characterized by a slightly dilated RV with preserved 
systolic function and normal filling pressures usually have 
preserved RV to PA coupling described by systolic and 
arterial elastance (11). RV to PA coupling is maintained 
at resting conditions for as long as the RV can adapt 
but not a sensitive parameter to identify an early disease 
state. 
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Non-pharmacological modulation of ANS in HF 
with pulmonary hypertension
The salutary effects of established pharmacotherapies 
for HF, including renin-angiotensin-aldosterone system 
inhibitors and beta-blockers, are demonstrated to be 
related to modulation of ANS tone and related reductions 
in arrhythmia and favorable ventricular remodeling, 
especially in systolic HF. Nowadays, there has been 
expanding interest in the non-pharmacological strategies 
to modulate ANS tone in patients with HF and pulmonary 
hypertension. In the study by Zhang et al., authors shown 
that PADN improved exercise capacity and reduced clinical 
events in left HF patients with combined pre- and post-
capillary pulmonary hypertension (CpcPH) accompanied 
with reduced left atrial pressure and dosage reduction of 
diuretics (12). Compared to sham PADN with sildenafil 
t rea tment ,  PADN improved  echocard iographic , 
hemodynamic and biological (NT-pro BNP) parameters at 
rest, leading to relief of symptoms and improved functional 
capacity at 6-month follow-up although 2 fatal pulmonary 
embolisms were occurred during the follow-up period. In 
patients with group 1 PAH sildenafil, an orally administered 
a selective inhibitor of 5-phosphodiesterase, targets the 
nitric oxide pathway and has been shown to increase 
pulmonary hemodynamics, functional capacity and survival. 
On the contrary, recent clinical trials have reported that 
there was no significant therapeutic effect of sildenafil on 
hemodynamics and functional capacity in HF (13). In the 
study by Wang et al., interestingly, the authors showed that 
the neutral effects of sildenafilo in HF could possibly be 
related to a negative impact on mitochondrial function and 
endoplasmic reticulum stress (14).
Vagal nerve stimulation (VNS) in patients with 
systolic HF
Because autonomic imbalance with increased adrenergic 
and reduced parasympathetic activity (via the vagus nerve) 
may affect cardiac contractility and sinoatrial function, 
modulation of the ANS via VNS has been identified as a 
potential therapeutic target in HF. Stimulation of the vagal 
nerve is obtained through an implantable stimulator system 
that delivers electrical impulses via a bipolar cuff electrode 
around the vagus nerve in the neck (3). In the INOVATE-
HF study by Gold et al., authors shown that, in chronic 
HF patients, VNS improved exercise capacity (6-minute 
walk distance), quality-of-life and NYHA functional class 
as pre-specified secondary endpoint at the 12-month 
visit, however, did not reduce the rate of death or HF 
events (15). Comparison of recent randomized controlled 
trials of sildenafil and non-pharmacological modulation 
of ANS in HF is summarized in Table 1 (12,13,15-17). 
Although PADN was shown to improve exercise capacity 
(6-minute walk distance) as primary end point in HF with 
CpcPH, further study is needed to determine the long-term 
survival benefit of PADN in the same patient cohort.
Potential mechanism of PADN in pulmonary 
hypertension
In most recent preclinical study using a rat model with 
PAH by Yoshida et al., the authors reported that VNS 
restored autonomic balance, decreased mean PA pressure, 
attenuated pulmonary vascular remodeling, and preserved 
RV function and also that VNS improved the survival 
rate in both the prevention and treatment protocols (8). 
Furthermore, in this study, acute VNS did not change 
nitric oxide synthesis or pulmonary vascular mechanics, 
despite  acute  as  wel l  as  chronic  VNS exhibit ing 
significant inflammatory suppression in rats with PAH. 
Potential mechanism of PADN with radiofrequency 
catheter ablation of the PA nerve plexuses in PA trunk 
in PAH might be similar to mechanism of VNS because 
both PADN and VNS has reported having little acute 
hemodynamic effect but improving hemodynamics, 
exercise capacity and symptoms at the 6-month follow-
up after intervention (12,15,18). What is more, favorable 
therapeutic effect of PADN in HF patients with CpcPH 
was observed in left atrial pressure (reduction of PCWP 
and mitral E/e’) leading to decreased PA pressure and 
PVR. In other words, PADN might have therapeutic effect 
in group 2 PAH. Of course, pathophysiological mechanism 
of elevating left atrial pressure is different between 
valvular heart disease and HF, and indeed between HF 
preserved and reduced ejection fraction. After all, because 
the precise underlying mechanisms of treatment effect of 
PADN has still reminded unclear, further study is needed 
to determine the salutary hemodynamic effects of PADN 
to improve clinical status in PAH patients irrespective of 
PAH phenotype. 
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MWD, minute wall distance; mPAP, mean pulmonary arterial pressure; PADN, pulmonary artery denervation; ANS, autonomic nervous 
system; HF, heart failure; VNS, vagal nerve stimulation.
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